Side effects of therapy for chronic hepatitis C.
Russo
Mark W
MW
Division of Digestive Diseases, University of North Carolina at Chapel Hill, 27599, USA.
Fried
Michael W
MW
D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D006402:Hematologic Diseases / Q000139:chemically induced; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects*; D008171:Lung Diseases / Q000139:chemically induced; D001523:Mental Disorders / Q000139:chemically induced; D009422:Nervous System Diseases / Q000139:chemically induced; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects*; D013959:Thyroid Diseases / Q000139:chemically induced
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a